Edition:
United States

Allergan plc (AGN)

AGN on New York Consolidated

214.78USD
17 Jan 2017
Change (% chg)

$-1.36 (-0.63%)
Prev Close
$216.14
Open
$214.40
Day's High
$215.88
Day's Low
$211.43
Volume
3,864,058
Avg. Vol
4,701,876
52-wk High
$301.98
52-wk Low
$184.50

Latest Key Developments (Source: Significant Developments)

Allergan says egregious price hikes by "outlier" companies hurting venture capital investment
Tuesday, 6 Sep 2016 11:14am EDT 

Allergan CEO, in interview: Says Allergan aims to limit annual price increases of branded therapeutic drugs to low to mid single digit percentage range, slightly above current annual rate of inflation . Says Allergan's planned price increase limits would be similar to company's price increases seen in 2016, and should follow in 2017, beyond . Says Hillary Clinton's plan for oversight panels to monitor, punish drugmakers that impose unreasonable price increases on life-saving drugs impractical in free market system . Says Clinton's proposal for emergency imports of drugs to ease drug shortages, prices could subject U.S. public to lower safety standards . Says publicity from "egregious" price increases of other companies have caused shrinkage of venture capital investment in new drugs .Says "outlier" companies that have drawn criticism for price hikes are endangering overall industry research and development.  Full Article

Allergan acquires gene therapy company Retrosense Therapeutics
Tuesday, 6 Sep 2016 08:00am EDT 

Allergan Plc : Allergan Acquires Gene Therapy Company Retrosense Therapeutics Adding First-In-Class technology to company's innovative eye care pipeline . Says under terms of transaction, Allergan has paid Retrosense a $60 million upfront payment . Says also has agreed to potential regulatory and commercialization milestone payments related to rst-001 .Says acquired substantially all of assets of Retrosense in an all-cash transaction.  Full Article

Allergan and Adamas enter settlement with Amneal Pharmaceuticals
Wednesday, 31 Aug 2016 08:00am EDT 

Allergan Plc : Allergan and Adamas announce settlement with Amneal related to namzaric patent litigation . Adamas will grant amneal a license to market generic versions of namzaric beginning on January 1, 2025 . Other terms of settlement were not disclosed . Under certain circumstances, amneal has an option to launch an authorized generic version of namzaric beginning on January 1, 2026 . Settlement provides additional clarity for patent-protected life of namzaric .Alternatively, under certain circumstances, amneal has option to launch authorized generic version of namzaric beginning on January 1, 2026.  Full Article

Allergan to acquire eye care company Forsight Vision5
Thursday, 11 Aug 2016 08:00am EDT 

Allergan PLC : Allergan to acquire eye care company Forsight Vision5 adding Peri-Ocular Ring Technology to company's leading portfolio of innovative eye health products . Under terms of agreement, Allergan will acquire Forsight Vision5 for a $95 million upfront payment and a launch milestone payment .Transaction is expected to be completed within 60 days.  Full Article

Allergan Equico reports 9.9 pct stake in Teva Pharmaceutical
Monday, 8 Aug 2016 06:15pm EDT 

Allergan :Reports a stake of 9.9 pct in Teva Pharmaceutical Industries Ltd as of July 27, 2016 - SEC filing.  Full Article

Allergan reports Q2 non-GAAP earnings per share of $3.35
Monday, 8 Aug 2016 07:00am EDT 

Allergan Plc : Allergan reports strong second quarter 2016 continuing operations performance with net revenues of $3.7 billion . Q2 revenue $3.7 billion . Company updates full-year 2016 continuing operations guidance . Q2 non-GAAP earnings per share $3.35 . Q2 loss per share $1.25 from continuing operations . Q2 earnings per share view $3.34 -- Thomson Reuters I/B/E/S . Sees full year GAAP and non-GAAP total reported net revenue $14.65 billion - $14.90 billion . Sees FY total branded net revenue $14.75 bln - $15 bln . Sees FY 2016 GAAP loss per share $1.95 - $2.15; sees FY 2016 non-GAAP earnings per share $13.75 - $14.20 . FY 2016 earnings per share view $14.19 -- Thomson Reuters I/B/E/S .Total net revenues in quarter were impacted by "loss of exclusivity on Namenda IR".  Full Article

Allergan Q2 non-GAAP earnings per share $3.35
Monday, 8 Aug 2016 07:00am EDT 

Allergan Plc : Allergan reports strong second quarter 2016 continuing operations performance with net revenues of $3.7 billion . Q2 non-GAAP earnings per share $3.35 . Q2 loss per share $1.25 from continuing operations . Q2 revenue $3.7 billion versus i/b/e/s view $4.08 billion . Q2 earnings per share view $3.34 -- Thomson Reuters I/B/E/S . GAAP total reported net revenues $14.65 billion - $14.90 billion . Total net revenues in quarter were impacted by "loss of exclusivity on Namenda IR" . Company updates full-year 2016 continuing operations guidance . Sees full-year total branded net revenue $14.75 billion- $15 billion . Sees 2016 GAAP loss per share of $1.95 - $2.15; sees 2016 non GAAP earnings per share of $13.75 - $14.20 .Full-year 2016 earnings per share view $14.19, revenue view $16.61 billion -- Thomson Reuters I/B/E/S.  Full Article

Allergan has no interest in a Biogen deal - CNBC, citing sources
Wednesday, 3 Aug 2016 09:38am EDT 

:Allergan has no interest in a Biogen deal - CNBC, citing sources.  Full Article

Allergan announces sale of Anda distribution business to Teva
Wednesday, 3 Aug 2016 07:00am EDT 

Allergan Plc : For Q2 of 2016, Anda is expected to contribute approximately $375 million in net revenues excluding sales of Allergan's branded products . For Q2 of 2016, Anda is expected to contribute approximately $0.05 in earnings per share . Allergan announces sale of Anda distribution business to Teva Pharmaceuticals . Allergan Plc says deal valued at $500 million . Anda to be reported as discontinued operations beginning with Q2 2016 earnings report on August 8, 2016 .For full year 2016, Anda is expected to contribute approximately $1.5 billion in third-party net revenue and approximately $0.15 in EPS.  Full Article

Allergan unlikely to pursue Biogen deal- CNBC,citing source
Tuesday, 2 Aug 2016 04:15pm EDT 

: Allergan unlikely to pursue Biogen deal- CNBC,citing source (Bengaluru Newsroom: +1-646-223-8780).  Full Article

Allergan to pay $15 mln over failing to disclose merger talks

WASHINGTON A unit of Botox maker Allergan Plc will pay a $15 million penalty and admit to wrongdoing, after U.S. regulators on Tuesday accused the unit of failing to disclose 2014 merger talks with Actavis, the U.S. Securities and Exchange Commission said.